Thrombosis research
-
Thrombosis research · Apr 2010
Meta AnalysisSafety of excluding acute pulmonary embolism based on an unlikely clinical probability by the Wells rule and normal D-dimer concentration: a meta-analysis.
The Wells clinical decision rule (CDR) and D-dimer tests can be used to exclude pulmonary embolism (PE). We performed a meta-analysis to determine the negative predictive value (NPV) of an "unlikely" CDR (
-
Thrombosis research · Apr 2010
The risk of false results in the assessment of platelet function in the absence of antiplatelet medication: comparison of the PFA-100, multiplate electrical impedance aggregometry and verify now assays.
Evaluation of aspirin (ASA) responsiveness with platelet function tests varies by the choice of blood mixture and functional test and cut off values for defining the the treatment used. Addition to that we also aimed to determine agreement between three tests and to research whether there is any necessity to measure baseline platelet activity. ⋯ Verify Now ASA assay, multiplate electrical impedance aggregometry and PFA-100 seem to be reliable tests in reflecting ASA effect on platelets. Cut off labels for the defining the responsiveness given by manufacturer may show significant interindividual variability with Verify Now ASA assay and multiplate electrical impedance aggregometry, and these test may show platelet inhibition despite the absence of ASA intake. Consideration of the pretreatment values may eliminate the risk of overestimation in the assessment of platelet inhibition by ASA.
-
Thrombosis research · Apr 2010
Thromboprophylaxis during chemotherapy in patients with advanced cancer.
Venous thromboembolism is a common and potentially fatal complication in patients with advanced cancer. In these patients chemotherapy has been identified as an independent risk factor for venous thromboembolism. The annual incidence of venous thromboembolism in cancer patients who receive chemotherapy is estimated to be about 10%. ⋯ The results of the PROTECHT study demonstrated that nadroparin reduces by 50% the rate of thromboembolic events in ambulatory patients with metastatic or locally advanced cancer while they receiving chemotherapy. The antithrombotic effect was more evident in patients with lung and gastrointestinal cancer. In future studies the clinical benefit of antithrombotic prophylaxis should be evaluated in cancer patients at particularly high risk for thromboembolism.
-
Thrombosis research · Apr 2010
Risk of thrombosis and infections of central venous catheters and totally implanted access ports in patients treated for cancer.
Thrombosis and infections are well known complications of central venous catheters and totally implanted access ports. These complications lead to increased costs due to prolonged hospitalisation, increased antibiotics use and need for replacement. The objectives of the study were to document the occurrence of catheter related thrombosis and infections in patients with central venous catheters and totally implanted chest ports in cancer patients and to investigate whether factor V Leiden is a risk factor for catheter related thrombosis. ⋯ A higher incidence of catheter related infections was observed in patients with central venous catheters in contrast to patients with totally implanted access ports were venous thrombosis was more frequent.